Amrize, Dexcom, Lennar
AMRZ•Analysts reportedly revised ratings and price targets for several U.S.-listed companies, including an Amrize coverage initiation at equal weight with a $55 target, a Dexcom target increase to $105 from $90, and a Lennar initiation at underweight with a $65 target.
1. Selected analyst actions
Barclays initiated coverage of Amrize with an equal-weight rating and a $55 price target. RBC raised its Dexcom price target to $105 from $90, while Morgan Stanley initiated coverage of Lennar with an underweight rating and a $65 target.
2. Other notable revisions
The roundup also listed Jefferies cutting Levi Strauss’ target to $25 from $27 and Deutsche Bank raising Synopsys’ target to $640 from $590. The full list included analyst rating and price-target actions across a range of U.S.-listed companies.
